The study found that the use of anti-CXCR3 monoclonal antibodies significantly reduced T cell migration and alleviated the severity of arthritis, including reductions in clinical symptoms, weight loss, and neutrophil accumulation in the joints. This evidence concerns the gene CXCR3 and arthritic joint disease.